{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'event of special interest and to characterize these', 'events', 'To compare the change of health related quality of life', '(HRQOL) from baseline in the Simultaneous versus', 'Sequential groups following the Vaccination Visit 1', '-', 'To assess the safety profiles in the simultaneous and', 'sequential group participants by baseline COVID-19', 'serostatus (positive versus negative)', '-', 'To assess the effect of simultaneous administration of', 'IIV4 and COVID-19 vaccine on IIV4 immunogenicity as', 'assessed by hemagglutination inhibition assay (HAI)', '-', 'To assess serum antibody levels to SARS-CoV-2', 'antigens*', 'Outcome Measures:', 'Primary Outcome Measure:', '-', 'Comparison of the proportion of participants reporting', 'at least one solicited reactogenicity event to include', 'fever, chills, myalgia, or arthralgia of moderate or', 'greater severity in the Simultaneous group with the', 'Sequential group within 1-7 days following both', 'Vaccination Visit 1 and Vaccination Visit 2', 'Secondary Outcome Measure:', '-', 'Comparison of the proportion of participants reporting', 'at least one solicited reactogenicity event to include', 'fever, chills, myalgia, or arthralgia of moderate or', 'greater severity in the Simultaneous group with the', 'Sequential group within 1-7 days following Vaccination', 'Visit 1 visit during which participants receive either IIV4', 'or placebo with an mRNA COVID-19 vaccine', 'Comparison of the proportion of participants reporting', 'at least one solicited reactogenicity event to include', 'fever, chills, myalgia, or arthralgia of moderate or', 'greater severity in the Simultaneous group with the', 'Sequential group within 1-7 days following Vaccination', 'Visit 2 during which participants receive either IIV4 or', 'placebo without an mRNA COVID-19 vaccine', 'The proportion of participants in each vaccination group', 'reporting specified solicited local and systemic', 'reactogenicity events of any severity and by severity', 'grade within 1-7 days following the first vaccination visit', 'during which participants receive either IIV4 or placebo', 'with an mRNA COVID-19 vaccine', 'The proportion of participants in each vaccination group', 'reporting specified solicited local and systemic', 'reactogenicity events of any severity and by severity', 'grade within 1-7 days following the second vaccination', 'visit during which participants receive either IIV4 or', 'placebo', '7']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '-', 'The proportion of participants in each vaccination group', 'reporting specified solicited local and systemic', 'reactogenicity events of any severity and by severity', 'grade within 1-7 days following the third vaccination', 'visit during which all participants receive an mRNA', 'COVID-19 vaccine alone for those receiving two doses', 'of mRNA COVID-19 vaccine', 'The proportion of participants in Simultaneous and', 'Sequential Groups with at least one serious adverse', 'event occurring during the study period and a', 'description of each event', 'Exploratory Outcome Measure:', '-', 'Comparison of the proportion of participants reporting', 'at least one solicited reactogenicity event to include', 'fever, chills, myalgia, or arthralgia of moderate or', 'greater severity in the Simultaneous group with the', 'Sequential group within 1-7 days following Vaccination', 'Visit 3 during which all participants receive an mRNA', 'COVID-19 vaccine alone for those receiving two doses', 'of mRNA COVID-19 vaccine', 'The proportion of participants reporting at least one', 'moderate or greater or at least one severe or greater', 'solicited local or systemic reactogenicity event in each', 'vaccination group within 1-7 days following the first', 'vaccination during which participants receive either IIV4', 'or placebo with an mRNA COVID-19 vaccine', 'The proportion of participants reporting at least one', 'moderate or greater or at least one severe or greater', 'solicited local or systemic reactogenicity event in each', 'vaccination group within 1-7 days following the second', 'vaccination visit which participants receive either IIV4', 'or placebo', 'The proportion of participants reporting at least one', 'moderate or greater or at least one severe or greater', 'solicited local or systemic reactogenicity event in each', 'vaccination group within 1-7 days following the third', 'vaccination visit during which all participants receive an', 'mRNA COVID-19 vaccine alone for those receiving two', 'doses of mRNA COVID-19 vaccine', 'The proportion of participants reporting at least one', 'moderate or greater or at least one severe or greater', 'solicited local or systemic reactogenicity event in each', 'vaccination group within 1-7 days following all', 'vaccination visits combined', '-', 'The proportion of participants in each vaccination group', 'with an unsolicited adverse event occurring during the 7', '8']\n\n###\n\n", "completion": "END"}